1
|
Marques DSC, Amorim CADC, Cruz Filho IJD, Silva RMFD, Santos FAB, Alves LC, Vasconcelos Alves IB, Junior SA, Lima MDCAD. Β-Lapachone-Dendrimer inclusion complex: Physicochemical characterization and its application against different evolutionary phases of Schistosoma mansoni. J Drug Deliv Sci Technol 2025; 104:106497. [DOI: 10.1016/j.jddst.2024.106497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2025]
|
2
|
Taio F, Converti A, Lima ÁAND. Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review. Int J Mol Sci 2024; 25:9511. [PMID: 39273458 PMCID: PMC11395308 DOI: 10.3390/ijms25179511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Revised: 08/25/2024] [Accepted: 08/27/2024] [Indexed: 09/15/2024] Open
Abstract
Cyclodextrins are ring-shaped sugars used as additives in medications to improve solubility, stability, and sensory characteristics. Despite being widespread, Chagas disease is neglected because of the limitations of available medications. This study aims to review the compounds used in the formation of inclusion complexes for the treatment of Chagas disease, analyzing the incorporated compounds and advancements in related studies. The databases consulted include Scielo, Scopus, ScienceDirect, PubMed, LILACS, and Embase. The keywords used were "cyclodextrin AND Chagas AND disease" and "cyclodextrin complex against Trypanosoma cruzi". Additionally, a statistical analysis of studies on Chagas disease over the last five years was conducted, highlighting the importance of research in this area. This review focused on articles that emphasize how cyclodextrins can improve the bioavailability, therapeutic action, toxicity, and solubility of medications. Initially, 380 articles were identified with the keyword "cyclodextrin AND Chagas disease"; 356 were excluded for not being directly related to the topic, using the keyword "cyclodextrin complex against Trypanosoma cruzi". Over the last five years, a total of 13,075 studies on Chagas disease treatment were found in our literature analysis. The studies also showed interest in molecules derived from natural products and vegetable oils. Research on cyclodextrins, particularly in the context of Chagas disease treatment, has advanced significantly, with studies highlighting the efficacy of molecules in cyclodextrin complexes and indicating promising advances in disease treatment.
Collapse
Affiliation(s)
- Fabrice Taio
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil
| | - Attilio Converti
- Department of Civil, Chemical and Environmental Engineering, Pole of Chemical Engineering, Genoa University, I-16145 Genoa, Italy
| | - Ádley Antonini Neves de Lima
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil
| |
Collapse
|
3
|
Nicoletti CD, Dos Santos Galvão RM, de Sá Haddad Queiroz M, Barboclher L, Faria AFM, Teixeira GP, Souza ALA, de Carvalho da Silva F, Ferreira VF, da Silva Lima CH, Borba-Santos LP, Rozental S, Futuro DO, Faria RX. Inclusion complex of O-allyl-lawsone with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifungal activity. J Bioenerg Biomembr 2023:10.1007/s10863-023-09970-x. [PMID: 37442875 DOI: 10.1007/s10863-023-09970-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 06/01/2023] [Indexed: 07/15/2023]
Abstract
The subclass naphthoquinone represents a substance group containing several compounds with important activities against various pathogenic microorganisms. Accordingly, we evaluated O-allyl-lawsone (OAL) antiparasitic and antifungal activity free and encapsulated in 2-hydroxypropyl-β-cyclodextrin (OAL MKN) against Trypanosoma cruzi and Sporothrix spp. OAL and OAL MKN were synthesized and characterized by physicochemical methods. The IC50 values of OAL against T. cruzi were 2.4 µM and 96.8 µM, considering epimastigotes and trypomastigotes, respectively. At the same time, OAL MKN exhibited a lower IC50 value (0.5 µM) for both trypanosome forms and low toxicity for mammalian cells. Additionally, the encapsulation showed a selectivity index approximately 240 times higher than that of benznidazole. Regarding antifungal activity, OAL and OAL MKN inhibited Sporothrix brasiliensis growth at 16 µM, while Sporothrix schenckii was inhibited at 32 µM. OAL MKN also exhibited higher selectivity toward fungus than mammalian cells. In conclusion, we described the encapsulation of O-allyl-lawsone in 2-hydroxypropyl-β-cyclodextrin, increasing the antiparasitic activity compared with the free form and reducing the cytotoxicity and increasing the selectivity towardSporothrix yeasts and the T. cruzi trypomastigote form. This study highlights the potential development of this inclusion complex as an antiparasitic and antifungal agent to treat neglected diseases.
Collapse
Grants
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- E-26/202.800/2017, SEI-260003/001178/2020, E-26/203.246/2017, E-26/203.246/2017, E-26/010.000984/2019, E-26/200.982/2021, E-26/010/00168/2015 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- 308755/2018-9, 301873/2019-4, and 308755/2018-9 Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 308755/2018-9, 301873/2019-4, and 308755/2018-9 Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 308755/2018-9, 301873/2019-4, and 308755/2018-9 Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collapse
Affiliation(s)
- Caroline Deckmann Nicoletti
- Faculdade de Farmácia, Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, 24241-000, Niterói, RJ, Brazil
| | - Raíssa Maria Dos Santos Galvão
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Campus Valonguinho, 24020-141, Niterói, RJ, Brasil
| | - Marcella de Sá Haddad Queiroz
- Faculdade de Farmácia, Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, 24241-000, Niterói, RJ, Brazil
| | - Lais Barboclher
- Faculdade de Farmácia, Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, 24241-000, Niterói, RJ, Brazil
| | - Ana Flávia Martins Faria
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Campus Valonguinho, 24020-141, Niterói, RJ, Brasil
| | - Guilherme Pegas Teixeira
- Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, n° 4365, Pavilhão Lauro Travassos, sala 01, 21040-900, Manguinhos, Rio de Janeiro, RJ, Brazil
| | - André Luis Ameida Souza
- Universidade Iguaçu, Nova Iguaçu - RJ, Av. Abílio Augusto Távora, 2134, 26260-045, Jardim Alvorada, Brazil
| | - Fernando de Carvalho da Silva
- Departamento de Quimica Orgânica, Universidade Federal Fluminense, Campus Valonguinho, 24020-141, Niterói, RJ, Brazil
| | - Vitor Francisco Ferreira
- Faculdade de Farmácia, Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, 24241-000, Niterói, RJ, Brazil
| | | | - Luana P Borba-Santos
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-170, Rio de Janeiro, RJ, Brazil
| | - Sonia Rozental
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-170, Rio de Janeiro, RJ, Brazil
| | - Débora Omena Futuro
- Faculdade de Farmácia, Departamento de Tecnologia Farmacêutica, Universidade Federal Fluminense, 24241-000, Niterói, RJ, Brazil
| | - Robson Xavier Faria
- Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Campus Valonguinho, 24020-141, Niterói, RJ, Brasil.
- Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, n° 4365, Pavilhão Lauro Travassos, sala 01, 21040-900, Manguinhos, Rio de Janeiro, RJ, Brazil.
| |
Collapse
|
4
|
Preparation, Characterization and Molecular Dynamics Simulation of Rutin-Cyclodextrin Inclusion Complexes. Molecules 2023; 28:molecules28030955. [PMID: 36770635 PMCID: PMC9919933 DOI: 10.3390/molecules28030955] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Revised: 01/12/2023] [Accepted: 01/16/2023] [Indexed: 01/20/2023] Open
Abstract
Rutin is a natural flavonoid that carries out a variety of biological activities, but its application in medicine and food is limited by its water solubility. One of the classical methods used to enhance drug solubility is encapsulation with cyclodextrins. In this paper, the encapsulation of different cyclodextrins with rutin was investigated using a combination of experimental and simulation methods. Three inclusions of rutin/beta-cyclodextrin (β-CD), rutin/2-hydroxypropyl beta-cyclodextrin (HP-β-CD) and rutin/2,6-dimethyl beta-cyclodextrin (DM-β-CD) were prepared by the freeze-drying method, and the inclusions were analyzed using Fourier infrared spectroscopy (FTIR), X-ray diffraction analysis (XRD), differential scanning calorimetry (DSC) and ultraviolet-visible spectroscopy (UV) to characterize and demonstrate the formation of the inclusion complexes. Phase solubility studies showed that rutin formed a 1:1 stoichiometric inclusion complex and significantly increased its solubility. β-CD, HP-β-CD, DM-β-CD, rutin and the three inclusion complexes were modeled by using MS2018 and AutoDock 4.0, and molecular dynamics simulations were performed to calculate the solubility parameters, binding energies, mean square displacement (MSD), hydrogen bonding and radial distribution functions (RDF) after the equilibration of the systems. The results of simulation and experiment showed that rutin/DM-β-CD had the best encapsulation effect among the three cyclodextrin inclusion complexes.
Collapse
|
5
|
de Andrade JKF, da Silva Góes AJ, Barbosa VX, de Lima Silva MS, Matos Donato MA, Peixoto CA, Militão GCG, da Silva TG. Anticancer activity of β-Lapachone derivatives on human leukemic cell lines. Chem Biol Interact 2022; 365:110057. [PMID: 35934135 DOI: 10.1016/j.cbi.2022.110057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 06/18/2022] [Accepted: 07/13/2022] [Indexed: 11/25/2022]
Abstract
β-lapachone is a 1,2-naphthoquinone of great therapeutic interest that induces cell death by autophagy and apoptosis in tumor cells due to oxidative stress increasing. However, its high toxicity in healthy tissues limits its clinical use, which stimulates the planning and synthesis of more selective analogs. The aim of this study was to investigate the cytotoxic activity of three thiosemicarbazones derived from β-lapachone (BV2, BV3 and BV5) in leukemia cells. Cytotoxicity tests were performed on tumor cells (HL-60, K562, K562-Lucena and MOLT-4) and normal peripheral blood mononuclear cells (PBMCs). Subsequently, the mode of action of compounds was accessed by optical microscopy, transmission electron microscopy or fluorescence microscopy. Flow cytometry analysis was performed to investigate apoptosis induction, cell cycle, DNA fragmentation and mitochondrial depolarization. All derivatives inhibited tumor cell growth after 72 h (IC50 < 10 μM to all cell lines, including the resistant K562-Lucena) with less toxic effects in PBMC cells, being BV3 the most selective compound with selective index (SI) of 275 for HL-60; SI of 40 to K562; SI of 10 for MOLT-4 and SI of 50 to K562-Lucena compared to β-lapachone with SI of 18 to HL-60, SI of 3.7 to K562; SI of 2.4 to MOLT-4 and SI of 0.9 to K562-Lucena. In addition, the K562 or MOLT-4 cells treated with BV3 showed characteristics of both apoptosis and autophagy cell death, mainly by autophagy. These results demonstrate the potent cytotoxic effect of thiosemicarbazones derived from β-lapachone as promising anticancer drugs candidates, encouraging the continuity of in vivo tests.
Collapse
Affiliation(s)
| | | | - Vanessa Xavier Barbosa
- Department of Antibiotics, Federal University of Pernambuco (UFPE), Recife, Pernambuco, 50670-901, Brazil
| | | | - Mariana Aragão Matos Donato
- Ultrastructure Laboratory, Aggeu Magalhães Research Center of the Oswaldo Cruz Foundation, Recife, Pernambuco, 50670-901, Brazil.
| | - Christina Alves Peixoto
- Ultrastructure Laboratory, Aggeu Magalhães Research Center of the Oswaldo Cruz Foundation, Recife, Pernambuco, 50670-901, Brazil.
| | | | | |
Collapse
|
6
|
Barbosa JMC, Nicoletti CD, da Silva PB, Melo TG, Futuro DO, Ferreira VF, Salomão K. Characterization and trypanocidal activity of a β-lapachone-containing drug carrier. PLoS One 2021; 16:e0246811. [PMID: 33661933 PMCID: PMC7932091 DOI: 10.1371/journal.pone.0246811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 01/26/2021] [Indexed: 12/12/2022] Open
Abstract
The treatment of Chagas disease (CD), a neglected parasitic condition caused by Trypanosoma cruzi, is still based on only two drugs, nifurtimox (Nif) and benznidazole (Bz), both of which have limited efficacy in the late chronic phase and induce severe side effects. This scenario justifies the continuous search for alternative drugs, and in this context, the natural naphthoquinone β-lapachone (β-Lap) and its derivatives have demonstrated important trypanocidal activities. Unfortunately, the decrease in trypanocidal activity in the blood, high toxicity to mammalian cells and low water solubility of β-Lap limit its systemic administration and, consequently, clinical applications. For this reason, carriers as drug delivery systems can strategically maximize the therapeutic effects of this drug, overcoming the above mentioned restrictions. Accordingly, the aim of this study is to investigate the in vitro anti-T. cruzi effects of β-Lap encapsulated in2-hydroxypropyl-β-cyclodextrin (2HP-β-CD) and its potential toxicity to mammalian cells.
Collapse
Affiliation(s)
- Juliana M. C. Barbosa
- Laboratório de Biologia Celular Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Caroline D. Nicoletti
- Laboratório de Síntese Orgânica Aplicada, Instituto de Química, Universidade Federal Fluminense, Niterói, RJ, Brazil
- Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil
| | - Patrícia B. da Silva
- Laboratório de Biologia Celular Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Tatiana G. Melo
- Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Débora O. Futuro
- Laboratório de Síntese Orgânica Aplicada, Instituto de Química, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Vitor F. Ferreira
- Laboratório de Síntese Orgânica Aplicada, Instituto de Química, Universidade Federal Fluminense, Niterói, RJ, Brazil
- Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil
| | - Kelly Salomão
- Laboratório de Biologia Celular Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|
7
|
da Silva Oliveira V, Dantas ED, de Sousa Queiroz AT, de Freitas Oliveira JW, de Sousa da Silva M, Ferreira PG, de Carvalho da Siva F, Ferreira VF, de Lima ÁAN. Novel Solid Dispersions of Naphthoquinone Using Different Polymers for Improvement of Antichagasic Activity. Pharmaceutics 2020; 12:pharmaceutics12121136. [PMID: 33255502 PMCID: PMC7760255 DOI: 10.3390/pharmaceutics12121136] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2020] [Revised: 11/19/2020] [Accepted: 11/20/2020] [Indexed: 11/17/2022] Open
Abstract
IVS320 (3a,10b-dihydro-1H-cyclopenta[b]naphtho[2,3-d]furan-5,10-dione) is a naphthoquinone that has low solubility in aqueous medium, a physical behavior that limits its biological activities, considering that compounds from this class have several activities. In this work, solid dispersions (SDs) prepared between IVS320 and polymers hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), and polyvinylpyrrolidone (PVP) were developed using physical mixture (PM), kneading (KN), and rotary evaporation (RE) methods. Dispersions were investigated using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thermogravimetry (TG), powder X-ray diffraction (PXRD), and scanning electron microscopy (SEM). In addition, in vitro antiparasitic activity in Trypanosoma cruzi Y strains was evaluated. Physical-chemical characterization demonstrated the formation of SDs through the interaction of IVS320 with polymeric matrices. SDs of IVS320-polymer presented a significant potentiation of antichagasic activity, with inhibitory growth around 62% (IVS320-HPMC/RE), 55% (IVS320-PEG/RE), and 85% (IVS320-PVP/RE), while pure IVS320 showed a value of 48% for the highest concentrations evaluated (50 µg/mL).
Collapse
Affiliation(s)
- Verônica da Silva Oliveira
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
| | - Elen Diana Dantas
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
| | - Anna Thereza de Sousa Queiroz
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
| | - Johny Wysllas de Freitas Oliveira
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
| | - Marcelo de Sousa da Silva
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
- Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, NOVA University Lisbon, 1800-166 Lisbon, Portugal
| | - Patricia Garcia Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Federal Fluminense University, Niterói, Rio de Janeiro 24241-002, Brazil; (P.G.F.); (V.F.F.)
| | | | - Vitor Francisco Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Federal Fluminense University, Niterói, Rio de Janeiro 24241-002, Brazil; (P.G.F.); (V.F.F.)
| | - Ádley Antonini Neves de Lima
- Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte 59012-570, Brazil; (V.d.S.O.); (E.D.D.); (A.T.d.S.Q.); (J.W.d.F.O.); (M.d.S.d.S.)
- Correspondence: ; Tel.: +55-84-99928-8864
| |
Collapse
|